Heterogeneity of CML therapy resistant cells
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
A deeper understanding of the biology of therapy resistant cells is important for the development of optimal therapeutic strategies to attain complete cure of leukemia. Here we compared chromatin accessibility of CML patient cells treated with Imatinib vs untreated cells and column enriched deep-quiescent LI (leukemia initiator) cells. ICG-001 treatment of LIs suggested increased differentiation of LIs. Overall design: CML patient cells were treated for 8 days with imatinib and therapy-resistant cells were MACS column enriched for CCR7+ deep quiescent LI (leukemia initiator) subset.
创建时间：
2023-03-30
